Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $83.05, for a total transaction of $2,076,250.00. Following the transaction, the executive vice president now directly owns 101,488 shares in the company, valued at approximately $8,428,578.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Gilead Sciences, Inc. (GILD) opened at 85.10 on Friday. The firm has a market cap of $111.13 billion, a P/E ratio of 9.24 and a beta of 1.19. The company’s 50-day moving average is $75.84 and its 200 day moving average is $69.71. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s revenue was down 8.2% compared to the same quarter last year. During the same period last year, the firm posted $3.08 earnings per share. Equities research analysts expect that Gilead Sciences, Inc. will post $8.74 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.44%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

WARNING: “Insider Selling: Gilead Sciences, Inc. (GILD) EVP Sells $2,076,250.00 in Stock” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/09/insider-selling-gilead-sciences-inc-gild-evp-sells-2076250-00-in-stock.html.

Several equities analysts have recently issued reports on GILD shares. Jefferies Group LLC reaffirmed a “hold” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 11th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 price objective (up previously from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 4th. Leerink Swann reaffirmed a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. Finally, BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Ten analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $83.06.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after buying an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. boosted its stake in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after buying an additional 310,607 shares in the last quarter. FMR LLC boosted its stake in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Finally, Parnassus Investments CA boosted its stake in Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares in the last quarter. 74.05% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.